Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Total Current Liabilities (2009 - 2025)

Grifols' (GIFLF) quarterly Total Current Liabilities came in at $2.4 billion in Q4 2025, up 2.01% on a YoY basis from $2.3 billion in Q4 2024, and up 2.01% quarter-over-quarter from $2.3 billion in Q4 2024.

Analysis

Grifols (GIFLF) Total Current Liabilities (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Total Current Liabilities for 17 consecutive years, with $2.4 billion the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 2.01% year-over-year to $2.4 billion; the trailing twelve-month figure through Dec 2025 stood at $2.4 billion (up 2.01% YoY), and the FY2025 full-year result was $2.3 billion, up 4753.38% from the prior year.
  • Total Current Liabilities climbed to $2.4 billion in Q4 2025 per GIFLF's latest filing, from $2.3 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $4.0 billion in Q4 2021 and bottomed at $2.1 billion in Q4 2022.
  • Historically, Total Current Liabilities has averaged $2.6 billion across 5 years, with a median of $2.4 billion in 2025.
  • The sharpest annual moves came in 2021 and 2022: Total Current Liabilities soared 149.68% in 2021, then slumped 48.17% in 2022.
  • Over 5 years, Total Current Liabilities stood at $4.0 billion in 2021, then plunged by 48.17% to $2.1 billion in 2022, then increased by 21.45% to $2.5 billion in 2023, then decreased by 7.92% to $2.3 billion in 2024, then climbed by 2.01% to $2.4 billion in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods registered $2.4 billion, $2.3 billion, and $2.5 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 25.50 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 11.02 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 3.94 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 5.53 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 1.58 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 2.53 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 1.51 Bn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 3.92 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn 283.60 Mn
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 2.35 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 2.35 Bn
Dec 31, 2024 2.30 Bn
Dec 31, 2023 2.50 Bn
Dec 31, 2022 2.06 Bn
Dec 31, 2021 3.97 Bn
Dec 31, 2020 1.59 Bn
Sep 30, 2020 1.45 Bn
Mar 31, 2020 1.47 Bn
Dec 31, 2019 1.51 Bn
Sep 30, 2019 1.55 Bn
Dec 31, 2018 91.37 Mn
Sep 30, 2018 1.26 Bn
Jun 30, 2018 96.90 Mn
Mar 31, 2018 1.49 Bn
Dec 31, 2017 1.15 Bn
Jun 30, 2017 85.29 Mn
Dec 31, 2016 1.16 Bn
Sep 30, 2016 97.13 Mn
Jun 30, 2016 132.34 Mn
Dec 31, 2015 1.15 Bn